Feline Immunodeficiency Virus (FIV): Viral Pathogenesis, Immune Evasion, and Diagnostics

Introduction

Feline immunodeficiency virus (FIV) is a lentivirus within the family Retroviridae that causes a progressive, multisystemic disease in domestic cats (Felis catus) and, to a lesser extent, in nondomestic felids. First isolated in 1986, FIV has since been recognized as a significant pathogen of global importance, with seroprevalence estimates varying widely by geographic region, population density, and lifestyle factors [1]. A systematic review and meta-analysis of global seroprevalence identified pooled estimates ranging from 2% to 30% in apparently healthy cats and up to 40% in high-risk populations [1]. Regional studies from France, Brazil, Italy, and Iran have further characterized the genetic diversity and seroprevalence of FIV in both domestic and outdoor cat populations [2, 3, 4, 5]. The virus shares structural and replicative features with human immunodeficiency virus (HIV), including a reliance on CD4+ T-lymphocytes for productive infection, but FIV does not use CD4 as a primary receptor; instead, it utilizes CD134 (OX40) and CXCR4 as entry co-receptors, enabling a broader host cell tropism [6].

This article provides an exhaustive review of FIV pathogenesis, immune evasion strategies, clinical staging, and modern diagnostic approaches, with an emphasis on the biophysical and molecular mechanisms underlying these processes.

Viral Pathogenesis

Viral Structure and Life Cycle

The FIV virion is an enveloped, spherical particle approximately 100-120 nm in diameter. The genome consists of two copies of positive-sense single-stranded RNA, approximately 9.4 kb in length, encoding the canonical retroviral genes gag, pol, and env, as well as several accessory genes including vif, rev, and orfA [6]. The Gag polyprotein is cleaved by the viral protease into matrix (MA), capsid (CA), and nucleocapsid (NC) proteins, which orchestrate virion assembly and genomic RNA packaging [7]. The NC domain of Gag contains zinc finger motifs that are essential for selective encapsidation of the viral RNA; chimeric studies between FIV and simian immunodeficiency virus (SIV) have revealed that the FIV NC zinc fingers can functionally replace those of SIV when the appropriate SP2 domain is present [8].

The FIV life cycle begins with attachment to the host cell via interactions between the envelope glycoprotein (SU) and the primary receptor CD134, followed by engagement of CXCR4 as a co-receptor. This binding triggers conformational changes that mediate fusion of the viral and cellular membranes. After entry, the viral RNA is reverse transcribed into double-stranded DNA by the viral reverse transcriptase, a process that is error-prone and contributes to the high genetic diversity of FIV [6]. The resulting proviral DNA is transported to the nucleus and integrated into the host genome by the viral integrase. Transcription of proviral DNA is regulated by the long terminal repeats (LTRs) and the viral transactivator Rev. Following translation, Gag and Gag-Pol polyproteins are transported to the plasma membrane, where assembly and budding occur. The viral protease matures the virion during or immediately after budding, rendering it infectious [6].

Cellular Tropism and CD4+ T-Cell Depletion

The primary target cells for FIV are activated CD4+ T-lymphocytes, but the virus also infects CD8+ T cells, B cells, macrophages, and dendritic cells due to the broad expression of CD134 [6]. The progressive depletion of CD4+ T cells is the hallmark of FIV pathogenesis and mirrors the immunopathogenesis of HIV. Several mechanisms contribute to this depletion:

• Direct cytopathic effect: High levels of viral replication lead to syncytium formation and cell lysis in activated CD4+ T cells.
• Immune-mediated destruction: Infected cells expressing viral antigens are targeted by cytotoxic T lymphocytes (CTLs) and natural killer cells.
• Apoptosis: Uninfected bystander CD4+ T cells undergo apoptosis due to chronic immune activation and dysregulation of cytokine networks.
• Impaired thymopoiesis: FIV infection disrupts thymic architecture and reduces the production of naive CD4+ T cells, limiting immune reconstitution.

The rate of CD4+ T-cell decline varies among individual cats and is influenced by viral subtype, host genetics, and co-infections. Longitudinal studies have demonstrated that cats with progressive FIV infection exhibit a continuous drop in CD4+/CD8+ ratios, a parameter used to stage disease severity [9]. Evaluation of leukocyte ratios has shown that inversion of the CD4+/CD8+ ratio is a strong predictor of survival in FIV-positive cats [9].

Genetic Diversity and Subtypes

FIV exhibits substantial genetic heterogeneity, with at least five distinct subtypes (A through E) and multiple recombinants circulating globally. Subtype B is most prevalent in Europe and the Americas, while subtype A predominates in Australia and parts of Asia [4]. Molecular detection and genotyping studies have identified both subtype B and recombinant forms in domestic cats from Iran and Italy [5, 4]. Subtype diversity has implications for diagnostic sensitivity: some antibody-based tests may fail to detect non-subtype B strains, underscoring the need for molecular assays in regions with high subtype variability.

Immune Evasion

FIV employs multiple strategies to evade and subvert the host immune response, enabling persistent infection despite robust antiviral immunity.

Tetherin Antagonism

Tetherin (BST-2) is an interferon-inducible host restriction factor that blocks the release of enveloped viruses by physically tethering budding virions to the cell surface. FIV counteracts tetherin via a mechanism that involves the envelope signal peptide. Morrison and Poeschla demonstrated that the FIV Env signal peptide functions as a tetherin antagonist, thereby facilitating efficient virion release [10]. This mechanism is distinct from the Vpu- or Nef-mediated tetherin antagonism used by HIV, highlighting a convergent evolutionary solution.

Latency and Immune Activation

Like other lentiviruses, FIV establishes latent infection in resting CD4+ T cells, creating a reservoir that is refractory to antiretroviral therapy and immune clearance. Proviral latency is maintained by epigenetic silencing of the LTR and lack of nuclear transcription factors in quiescent cells. Periodic reactivation of latency due to antigenic stimulation leads to bursts of viral replication that drive chronic immune activation. This persistent activation results in exhaustion of virus-specific T cells and progressive immune dysfunction.

Epitope Variation and Glycan Shielding

The envelope glycoprotein of FIV is highly variable, particularly in the V3 and V4 loops of SU. This variability allows the virus to escape neutralizing antibody responses. Additionally, extensive N-linked glycosylation of the envelope proteins forms a glycan shield that limits antibody access to conserved epitopes. The combination of epitope variation and glycan shielding facilitates prolonged evasion of humoral immunity.

Clinical Staging and Disease Associations

Clinical staging of FIV infection follows a pattern analogous to HIV, with four distinct phases:

The clinical progression is highly variable and influenced by age at infection, strain virulence, and co-infections such as feline leukemia virus (FeLV). A study from southern Brazil reported that FIV-positive cats were significantly more likely to present with oral lesions, chronic upper respiratory tract signs, and weight loss compared to uninfected controls [3].

Non-Lymphoid Complications

Recent research has expanded the spectrum of FIV-associated disease beyond the immune system. Prisco et al. described inflammatory myopathy and myocarditis as relevant complications of natural FIV infection, with histopathological evidence of multifocal mononuclear cell infiltration in skeletal and cardiac muscle [11]. These findings suggest that FIV contributes to systemic inflammatory pathology beyond lymphoid organs.

Cognitive and behavioral changes have also been documented. Azadian and Gunn-Moore identified age-related cognitive impairments in FIV-positive cats, including deficits in spatial learning and memory [12]. Furthermore, FIV envelope glycoproteins have been shown to promote tau pathology in neurons via cGMP-dependent kinase II activation, a mechanism shared with HIV [13].

Coinfections and Oral Health

FIV-positive cats are at increased risk for periodontal disease. Bashor et al. investigated the impact of antiretroviral therapy on the oral microbiome and periodontal health of FIV-positive cats and found that combination antiretroviral therapy altered the bacterial composition but did not fully reverse disease severity [14]. The oral cavity serves as a site of persistent viral replication and microbial dysbiosis, contributing to chronic inflammation.

FIV in Nondomestic Felids

FIV infection occurs in many nondomestic felid species, including lions (Panthera leo). A case-control study in Australian lions found increased seroprevalence but no clear association between FIV infection and clinical disease, suggesting that some species may host FIV without overt pathology [15]. This tolerance may reflect long-term coadaptation between virus and host.

Diagnostics

Serological Assays: Antibody Detection

The standard screening method for FIV is detection of serum antibodies against viral core (p24, p15) and envelope (gp40, gp120) proteins. Commercial enzyme-linked immunosorbent assay (ELISA) kits and lateral flow immunoassays (point-of-care tests) are widely used in veterinary practice. However, not all assays perform equivalently.

Laska-Modzelewska et al. conducted a comparative evaluation of nine lateral flow assays for FIV antibody detection using an in-house ELISA as a reference method [16]. Sensitivity and specificity varied markedly among brands, ranging from 70% to 98% and 85% to 100%, respectively. False negatives were more common in samples from cats infected with subtypes other than B, highlighting the importance of selecting assays with broad subtype recognition. The study recommended that negative results from lateral flow tests be confirmed by a reference ELISA or PCR in high-prevalence populations.

ELISA formats typically use recombinant or purified viral antigens coated on microtiter plates. Detection of antibodies to the immunodominant p24 capsid protein provides the highest sensitivity. A detailed discussion of ELISA principles as applied to retrovirus diagnostics can be found in the article Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus, which covers antigen capture methodologies that are conceptually similar to those used for FIV antibody detection.

Molecular Methods: PCR and Sequencing

Polymerase chain reaction (PCR) is the method of choice for detecting proviral DNA or viral RNA in blood, saliva, or tissue samples. PCR can confirm infection in serologically negative cats during the early window period (first 2-6 weeks post-infection) and is essential for diagnosing infection in kittens born to FIV-positive queens (maternal antibodies may cause false positive serology). Several nested and real-time PCR protocols target conserved regions of the gag or pol genes.

Molecular detection and genotyping studies have used PCR with subsequent sequencing to characterize circulating subtypes. Balboni et al. amplified a fragment of the env gene from seropositive cats in northern Italy and identified subtype B as predominant [4]. Mortazavi et al. used a similar approach to detect FIV provirus in cats from Tehran, finding both subtype B and recombinant sequences [5]. PCR-based methods are also essential for monitoring viral load in experimental settings and for confirming infection in nondomestic felids [15].

Diagnostic Algorithm

A rational diagnostic approach combines serological screening with confirmatory molecular testing. The following Mermaid diagram illustrates a recommended workflow.

flowchart TD
    A[Clinical suspicion or routine screening], > B[Perform lateral flow antibody test]
    B, > C{Result}
    C, >|Positive| D[Interpret as FIV antibody positive]
    D, > E[Confirm with ELISA or PCR if clinical discordance or subtype concern]
    C, >|Negative but high risk| F[Repeat test after 4-6 weeks or perform PCR]
    C, >|Negative low risk| G[No further action]
    E, > H[Positive: FIV-infected / Negative: false positive serology?]
    H, >|Positive| I[Stage disease and manage accordingly]
    H, >|Negative| J[Investigate other causes of clinical signs]
    F, > K[PCR proviral DNA detection]
    K, > L{Result}
    L, >|Positive| I
    L, >|Negative| M[Consider seroconversion window or recent infection; retest]

Interpretation Caveats

Interpretation of serological results must consider several factors:

• Kittens younger than 6 months may test positive due to passively acquired maternal antibodies; PCR is recommended to determine infection status.
• Vaccination against FIV (killed whole-virus vaccine) produces antibodies indistinguishable from those induced by natural infection. Vaccinated cats will test positive on antibody-based assays for years. PCR can differentiate vaccine from natural infection because vaccine-derived DNA is not present.
• In regions with low seroprevalence, the positive predictive value of lateral flow assays decreases; confirmatory testing is advised.

Recent advances in point-of-care molecular diagnostics, as discussed in the article Point-of-Care Molecular Diagnostics for Feline Upper Respiratory Pathogens, suggest that integrated nucleic acid amplification platforms for FIV detection may become available in clinical settings, further improving diagnostic accuracy for this retrovirus.

Conclusion

Feline immunodeficiency virus remains a significant pathogen with complex pathogenic mechanisms and ongoing challenges in diagnosis and management. The progressive depletion of CD4+ T cells, combined with sophisticated immune evasion strategies such as tetherin antagonism and glycan shielding, underlies the chronic and often debilitating course of infection. Clinical staging provides a framework for prognosis, while recent literature has expanded the recognized disease associations to include inflammatory myopathy, myocarditis, and cognitive decline. Diagnostic reliability depends on the appropriate selection and interpretation of serological and molecular tests, with reference methods essential for resolving equivocal results. Continued surveillance of genetic diversity and refinement of diagnostic tools will be critical for controlling FIV in domestic and wild felid populations.

References

[1] Bezerra JAB, Limeira CH, Maranhão ACPM, et al. Global seroprevalence and factors associated with seropositivity for feline immunodeficiency virus (FIV) in cats: A systematic review and meta-analysis. Prev Vet Med. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39146687/

[2] Bessière P, Hayes B, Fusade-Boyer M, et al. Seroprevalence and genetic diversity of feline immunodeficiency virus in outdoor cats in France. Vet Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41345889/

[3] de Mello LS, Diesel LP, de Oliveira Santana W, et al. Feline immunodeficiency virus (FIV): Prevalence, risk factors, and clinical findings in domestic cats (Felis catus) from southern Brazil. Comp Immunol Microbiol Infect Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39647437/

[4] Balboni A, Facile V, Gallina L, et al. Molecular Detection and Genetic Characterization of Feline Immunodeficiency Virus (FIV) in Seropositive Cats in Northern Italy. Pathogens. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38921761/

[5] Mortazavi M, Staji H, Tamai IA. Molecular detection and genotyping of feline immunodeficiency virus (FIV) in domestic cats from Tehran, Iran. Comp Immunol Microbiol Infect Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41386113/

[6] González SA, Affranchino JL. The life cycle of feline immunodeficiency virus. Virology. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39561619/

[7] Krishnan A, Ali LM, Prabhu SG, et al. Identification of a putative Gag binding site critical for feline immunodeficiency virus genomic RNA packaging. RNA. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37914398/

[8] González SA, Affranchino JL. The assembly-defective phenotype of an FIV Gag polyprotein containing the SIV nucleocapsid zinc finger motifs is reversed by including the SIV SP2 domain in the chimeric protein. Virology. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38959724/

[9] Rossi A, Proverbio D, Perego R, et al. Evaluation of leukocyte ratios as survival prognostic markers in feline retrovirus infections. Vet J. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38754624/

[10] Morrison JH, Poeschla EM. The Feline Immunodeficiency Virus Envelope Signal Peptide Is a Tetherin Antagonizing Protein. mBio. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36927083/

[11] Prisco F, Vaccaro E, Cardillo L, et al. Inflammatory myopathy and myocarditis are relevant complications of natural feline immunodeficiency virus infection. Vet Pathol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40407148/

[12] Azadian A, Gunn-Moore DA. Age-related cognitive impairments in domestic cats naturally infected with feline immunodeficiency virus. Vet Rec. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35512238/

[13] Sathler MF, Doolittle MJ, Cockrell JA, et al. HIV and FIV glycoproteins increase cellular tau pathology via cGMP-dependent kinase II activation. J Cell Sci. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35638570/

[14] Bashor L, Rawlinson JE, Kozakiewicz CP, et al. Impacts of Antiretroviral Therapy on the Oral Microbiome and Periodontal Health of Feline Immunodeficiency Virus-Positive Cats. Viruses. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40007012/

[15] Dabydeen A, Herrin KV, Woolfenden L, et al. Investigations into disease associations with feline immunodeficiency virus (FIV) infection in lions (Panthera leo) in Australia: a case-control study. Aust Vet J. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39601718/

[16] Laska-Modzelewska A, Pawelczak P, Jank M, et al. Comparative evaluation of nine lateral flow assays for FIV antibody detection using an in-house ELISA as a reference method. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41572271/

[17] Akhtar N, Mishra R, Tripathi S, et al. Feline immunodeficiency virus: current insights into pathogenesis, clinical impact, and advances in treatment and vaccine development. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41078490/

[18] Barbosa WZ, Magalhães KA, Pussi KF, et al. Feline immunodeficiency virus, feline leukemia virus and Leishmania spp. prevalence in cats from shelters in Mato Grosso do Sul, Brazil. Rev Bras Parasitol Vet. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38958295/

[19] Kim J, Behzadi ES, Nehring M, et al. Combination Antiretroviral Therapy and Immunophenotype of Feline Immunodeficiency Virus. Viruses. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37112803/

[20] Acevedo-Jiménez GE, Sarmiento-Silva RE, Alonso-Morales RA, et al. Detection and genetic characterization of feline retroviruses in domestic cats with different clinical signs and hematological alterations. Arch Virol. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36534205/